Blueprint medicines corporation (BPMC)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities
Net loss

-371,242

-347,694

-361,685

-340,133

-267,500

-236,642

-205,347

-170,327

-176,691

-148,119

-120,355

-99,486

-84,968

-72,495

-66,807

-62,615

-56,701

-52,769

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

5,652

5,259

8,504

7,062

4,644

4,246

3,467

2,700

1,960

1,578

1,580

1,591

1,594

1,582

1,522

1,319

1,125

948

0

0

0

Noncash lease expense

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Noncash interest expense

-

-

-

-

-

-

-

-

-

-

-

0

62

-

84

93

102

109

0

0

0

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

445

0

0

0

Stock-based compensation

61,217

54,653

47,786

41,184

35,280

30,534

25,407

20,615

15,832

12,523

10,464

8,770

7,278

6,140

5,689

4,755

5,442

5,180

0

0

0

Accretion of premiums and discounts on investments

-3,751

-4,949

-5,813

-5,679

-5,021

-4,381

-3,220

-2,071

-1,098

-320

63

267

352

301

0

0

0

-

-

-

-

Other

-

-

-

-

-

-6

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Changes in assets and liabilities:
Accounts receivable

4,123

599

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unbilled accounts receivable

20,226

22,597

0

0

0

-

-

-

-

-3,577

0

0

-1,406

-

985

1,428

3,748

3,414

0

0

0

Inventory

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

3,365

3,338

7,096

1,429

-1,232

-6,086

674

1,570

1,408

6,853

-425

3,244

2,927

-1,307

-272

-1,100

-1,144

1,482

0

0

0

Other assets

-68

-20

35

837

4,329

4,242

3,923

4,046

499

458

1,099

283

301

304

0

0

0

-

-

-

-

Accounts payable

4,181

1,448

-1,784

3,631

1,019

-445

1,901

450

979

1,532

252

-126

-492

4

334

1,037

441

1,391

0

0

0

Accrued expenses

21,612

36,980

32,286

23,203

24,121

24,804

24,447

22,239

15,624

14,597

12,922

7,524

4,542

5,773

2,339

3,702

1,750

1,956

0

0

0

Deferred revenue

62

-94

-5,869

-3,825

5,702

5,479

5,114

1,576

-9,800

-11,861

-14,576

-11,648

-12,548

33,594

36,487

37,235

41,936

13,641

0

0

0

Deferred rent

-

-

-

-

-

-640

7,545

13,648

14,315

14,320

6,188

118

-505

-488

2,101

2,637

2,793

2,871

0

0

0

Operating lease liabilities

-2,199

-2,095

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-307,155

-278,015

-300,702

-284,003

-205,634

-175,009

-142,177

-113,690

-138,348

-119,865

-103,912

-96,028

-86,344

-24,513

-18,762

-12,593

-5,815

-31,676

0

0

0

Purchases of property and equipment

13,768

14,013

10,547

6,983

8,135

12,677

22,832

24,689

21,614

15,512

4,950

997

1,302

2,354

6,090

6,390

6,126

4,883

0

0

0

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-189

-189

-189

1,196

0

0

0

Purchases of investments

764,721

738,387

749,848

777,240

575,336

801,236

694,449

640,228

681,648

360,835

474,437

405,137

213,248

264,467

0

0

0

-

-

-

-

Maturities of investments

732,569

735,934

732,434

698,315

730,825

652,825

549,825

473,000

376,000

304,000

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by investing activities

-45,920

-16,466

-27,961

-85,908

147,354

-161,088

-167,456

-191,917

-327,262

-72,347

-260,506

-268,253

-112,669

-218,821

-84,219

-69,423

-75,159

-6,079

0

0

0

Principal payments on loan payable

-

-

-

-

-

1,528

1,833

1,999

2,167

2,583

2,833

3,083

3,333

3,333

3,056

2,640

2,222

1,806

0

0

0

Payment of offering costs

-

-

-

-

-

281

323

530

640

965

0

0

0

-

-

-

-

2,046

0

0

0

Proceeds from public offerings of common stock, net of commissions, underwriting discounts and offering costs

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of Series C convertible preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from issuance of common stock

0

-

-

-

0

-

-

-

8,012

5,271

3,299

2,239

1,801

928

660

536

269

259

0

0

0

Other financing activities

-

-116

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

648,777

340,638

339,568

335,186

3,403

4,454

331,543

331,802

547,430

543,948

350,725

349,622

132,961

132,577

-2,396

-2,185

152,965

153,222

0

0

0

Net increase in cash, cash equivalents, and restricted cash

295,702

46,157

10,905

-34,725

-54,877

-331,643

21,910

26,195

81,820

351,736

-13,693

-14,659

-66,052

-110,757

-105,377

-84,201

71,991

115,467

0

0

0

Effect of exchange rate changes on cash, cash equivalents and restricted cash

84

18

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental cash flow information
Public offering costs incurred but unpaid at period end

0

-

-

-

-

-

-

-

-33

317

0

0

0

-

-

-

-

-

-

0

0

Property and equipment purchases unpaid at period end

-55

958

4,009

2,126

-736

912

879

4,141

6,993

3,947

0

0

0

-

0

0

0

-

-

-

-

Cash paid for interest

-

-

-

-

-

267

87

91

119

151

187

227

271

316

359

396

427

452

0

0

0

Cash paid for taxes, net

164

185

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-